Prothena Corp Public Ltd Co (PRTA) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
High 8.55 at 4:00 pm ET, low 8.29 at 10:00 am ET.
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
the bull case· 2
12
supplier and customer ties disclosed in SEC filings
sec filingsedgar+2.90%
shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26the bear case· 3
8 of 8
recent reports where the move came in under the options implied range
earnings historyimplied vs realized0.13%
of State Street SPDR S&P Biotech ETF's assets, the largest fund weight on file
n-portJun 30 '268 of 25
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 5 '26 report. Not a forecast, not advice.
Of the 6 companies Prothena Corp Public Ltd Co moves with most closely, none share its SEC classification.
Measured against 499 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
Prothena Corp Public Ltd Co
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
tall tick = annual report · 1 on record
189 managers report a position worth $472.9M between them, and 22 of them hold 80% of it.
PRTA (Prothena Corp Public Ltd Co) has 9 disclosed suppliers and 3 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.